Incyte Corporation $INCY Stock: Jefferies Financial Group Inc. Reduces Stake

Jefferies Financial Group Inc. lowered its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 60.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 60,136 shares of the biopharmaceutical company’s stock after selling 92,663 shares during the period. Jefferies Financial Group Inc.’s holdings in Incyte were worth $7,298,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Incyte during the second quarter worth approximately $2,044,189,000. Legal & General Group Plc bought a new stake in shares of Incyte in the 2nd quarter worth approximately $182,054,000. Caisse de depot et placement du Quebec bought a new stake in shares of Incyte in the 2nd quarter worth approximately $155,360,000. Deutsche Bank AG purchased a new stake in shares of Incyte in the 2nd quarter valued at $143,172,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Incyte in the 2nd quarter valued at $110,279,000. 96.97% of the stock is currently owned by institutional investors.

Incyte Stock Performance

NASDAQ:INCY opened at $121.70 on Friday. The firm has a market cap of $24.81 billion, a PE ratio of 64.73, a price-to-earnings-growth ratio of 4.45 and a beta of 0.78. Incyte Corporation has a fifty-two week low of $89.25 and a fifty-two week high of $132.60. The business has a 50 day moving average price of $119.32 and a 200-day moving average price of $108.87.

Incyte (NASDAQ:INCY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter last year, the business earned $2.26 earnings per share. The business’s revenue was up 14.0% on a year-over-year basis. Research analysts predict that Incyte Corporation will post 2.24 EPS for the current year.

Analysts Set New Price Targets

INCY has been the topic of several recent research reports. Sanford C. Bernstein increased their target price on shares of Incyte from $104.00 to $108.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. Barclays boosted their price target on shares of Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Zacks Research lowered shares of Incyte from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th. Guggenheim raised their price objective on Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley started coverage on Incyte in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Incyte currently has a consensus rating of “Hold” and a consensus target price of $132.86.

Read Our Latest Stock Report on INCY

Insider Buying and Selling at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 2,642 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the transaction, the insider owned 183,200 shares in the company, valued at approximately $20,648,472. The trade was a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 254,246 shares of company stock valued at $30,162,968 in the last quarter. Company insiders own 16.20% of the company’s stock.

Incyte Profile

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Further Reading

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.